World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
78
Citations
25061
World Ranking
1737
National Ranking
854

Michael R. Loken publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Michael R. Loken sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 69 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 317 publications — 67th percentile

67% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Michael R. Loken D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Michael R. Loken sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 163 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 78 D-Index — 65th percentile

65% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Research.com Recognitions

  • 2008 - Fellow of the Indian National Academy of Engineering (INAE)

Overview

Michael R. Loken is affiliated with the Fred Hutchinson Cancer Research Center in the United States. Their research primarily focuses on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant contributions to subfields such as Hematology, Molecular Biology, Oncology, Public Health, Environmental and Occupational Health, and Genetics.

The scientist's work covers a range of topics within hematologic malignancies and related therapies, including:

  • Acute Myeloid Leukemia Research
  • Acute Lymphoblastic Leukemia Research
  • CAR-T Cell Therapy Research
  • Hematopoietic Stem Cell Transplantation
  • Chronic Myeloid Leukemia Treatments
  • Multiple Myeloma Research and Treatments
  • Histone Deacetylase Inhibitors Research

Loken has published extensively on these topics, with frequent appearances in journals such as:

  • Blood
  • Cytometry Part B Clinical Cytometry
  • Blood Advances
  • Pediatric Blood & Cancer
  • Haematologica

Among Loken's recent papers are:

  • Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's Oncology Group, 2020, Haematologica
  • CEBPA-bZip mutations are associated with favorable prognosis in de novo AML: a report from the Children's Oncology Group, 2021, Blood
  • Comprehensive molecular and clinical characterization of NUP98 fusions in pediatric acute myeloid leukemia, 2023, Haematologica
  • A longitudinal single-cell atlas of treatment response in pediatric AML, 2023, Cancer Cell
  • Cytokine-mediated CAR T therapy resistance in AML, 2024, Nature Medicine

They have collaborated frequently with other researchers, including:

  • Lisa Eidenschink Brodersen
  • Soheil Meshinchi
  • Laura Pardo
  • Todd A. Alonzo
  • E. Anders Kolb

Michael R. Loken was awarded the Fellow of the Indian National Academy of Engineering (INAE) in 2008.

Best Publications

  • Characterization of the murine T cell surface molecule, designated L3T4, identified by monoclonal antibody GK1.5: similarity of L3T4 to the human Leu-3/T4 molecule.

    D P Dialynas;Z S Quan;K A Wall;A Pierres

  • The relationship of CD16 (Leu-11) and Leu-19 (NKH-1) antigen expression on human peripheral blood NK cells and cytotoxic T lymphocytes

    L. L. Lanier;An My Le;C. I. Civin;M. R. Loken

  • Characterization of the Murine Antigenic Determinant, Designated L3T4a, Recognized by Monoclonal Antibody GK 1.5: Expression of L3T4a by Functional T Cell Clones Appears to Correlate Primarily with Class II MHC Antigen‐Reactivity

    D. P. Dialynas;D. B. Wilde;P. Marrack;A. Pierres

  • Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells.

    Leon W.M.M. Terstappen;Shiang Huang;Meredith Safford;Peter M. Lansdorp

  • Flow cytometric analysis of human bone marrow. II. Normal B lymphocyte development.

    Michael R. Loken;Virendra O. Shah;Virendra O. Shah;Karen L. Dattilio;Karen L. Dattilio;Curt I. Civin;Curt I. Civin

  • Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

    Richard A. Larson;Eric L. Sievers;Eric L. Sievers;Edward A. Stadtmauer;Bob Löwenberg

  • ANALYSIS OF CELL POPULATIONS WITH A FLUORESCENCE‐ACTIVATED CELL SORTER*

    Michael R. Loken;Leonard A. Herzenberg

  • Myeloid and monocytic dyspoiesis as determined by flow cytometric scoring in myelodysplastic syndrome correlates with the IPSS and with outcome after hematopoietic stem cell transplantation.

    Denise A. Wells;Martin Benesch;Michael R. Loken;Carlos Vallejo

  • Flow cytometric analysis of human bone marrow: I. Normal erythroid development

    Michael R. Loken;Michael R. Loken;Virendra O. Shah;Virendra O. Shah;Karen L. Dattilio;Karen L. Dattilio;Curt I. Civin;Curt I. Civin

  • Establishing optimal lymphocyte gates for immunophenotyping by flow cytometry

    Michael R. Loken;Jeanne M. Brosnan;Bruce A. Bach;Kenneth A. Ault

  • A role for tumour necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome

    Geoffrey M. Gersuk;Cassandra Beckham;Michael R. Loken;Peter Kiener

  • Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.

    Michael R. Loken;Todd A. Alonzo;Todd A. Alonzo;Laura Pardo;Robert B. Gerbing

  • Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

    R A Larson;Marc Boogaerts;E Estey;C Karanes

  • Identification and characterization of plasma cells in normal human bone marrow by high-resolution flow cytometry

    Leon W.M.M. Terstappen;Steen Johnsen;Ine M.J. Segers-Nolten;Michael R. Loken

  • Flow cytometry as an analytical and preparative tool in immunology.

    Michael R. Loken;Alan M. Stall

  • Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes

    Arjan A. van de Loosdrecht;Canan Alhan;Marie Christine Béné;Matteo G. Della Porta

  • Flow cytometric analysis of human bone marrow. III. Neutrophil maturation.

    L. W. M. M Terstappen;M Safford;M. R Loken

  • Antigenic analysis of hematopoiesis. VI. Flow cytometric characterization of My-10-positive progenitor cells in normal human bone marrow.

    C I Civin;M L Banquerigo;L C Strauss;M R Loken

  • Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia

    Mohamed L. Sorror;Michael B. Maris;Brenda M. Sandmaier;Barry E. Storer

  • CD33 expression and P-glycoprotein–mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy

    Roland B. Walter;Roland B. Walter;Ted A. Gooley;Vincent H. J. van der Velden;Michael R. Loken

  • CD45 Gating for Routine Flow Cytometric Analysis of Human Bone Marrow Specimens

    Gregory T. Stelzer;Keith E. Shults;Michael R. Loken

Frequent Co-Authors

Todd A. Alonzo
Todd A. Alonzo University of Southern California
Susana C. Raimondi
Susana C. Raimondi St. Jude Children's Research Hospital
Betsy A. Hirsch
Betsy A. Hirsch University of Minnesota
Leon W.M.M. Terstappen
Leon W.M.M. Terstappen University of Twente
Irwin D. Bernstein
Irwin D. Bernstein Fred Hutchinson Cancer Research Center
Curt I. Civin
Curt I. Civin University of Maryland, Baltimore
Lillian Sung
Lillian Sung University of Toronto
H. Joachim Deeg
H. Joachim Deeg Fred Hutchinson Cancer Research Center
Frank W. Fitch
Frank W. Fitch University of Chicago
Frederick R. Appelbaum
Frederick R. Appelbaum Fred Hutchinson Cancer Research Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those exploring Immunology, related healthcare degrees offer valuable pathways to specialized careers. Many students interested in clinical and research roles consider nursing programs as a complementary option. For instance, online ABSN programs for non nurses provide a rapid route for individuals without a nursing background to transition into the nursing profession, blending foundational knowledge with hands-on skills.

When considering accelerated nursing options, the easiest accelerated nursing programs to get into can offer a smoother admission process, making it accessible to a broader range of applicants. These programs allow students to earn their degrees faster, which can be ideal for those eager to enter the workforce or pivot their career focus.

Entry-level nursing roles are also crucial in healthcare teams closely working with immunology patients. LPN programs with easiest admission requirements can be an excellent starting point for those seeking quick entry into the field while building practical experience that may lead to advanced study.

For those aiming to specialize further, the easiest FNP program (Family Nurse Practitioner) offers a streamlined path to advanced practice nursing. FNPs often work with immunocompromised patients, making this degree highly relevant in the immunology landscape.

Best Scientists Citing Michael R. Loken

Trending Scientists